AIDS-Related Cancers - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Treating KSHV-Associated Multicentric Castleman Disease
(Posted: 09/18/2012) - In this pilot study, patients with KSHV-associated multicentric Castleman disease will receive intravenous tocilizumab every other week for up to 12 weeks. Patients who do not benefit from tocilizumab therapy alone may go on to receive high-dose AZT and valganciclovir in addition to tocilizumab.
- Combination Therapy for Advanced Kaposi Sarcoma
(Posted: 11/16/2010) - In this clinical trial, adult patients with any form of advanced Kaposi sarcoma will be treated with liposomal doxorubicin and bevacizumab every 3 weeks for a maximum of six treatments. Patients who respond to this therapy or have stable disease will receive bevacizumab alone every 3 weeks for a maximum of 11 treatments.
- Biological Therapy to Treat Kaposi Sarcoma
(Posted: 08/03/2004, Updated: 09/23/2010) - Researchers with this study are investigating whether bevacizumab (Avastin®), a type of biological agent that blocks the formation and growth of new blood vessels, is effective in the treatment of Kaposi sarcoma (KS). Blood vessel cells are the main component of KS lesions.
- Sorafenib for Kaposi's Sarcoma
(Posted: 01/30/2007) - In this trial, patients with either AIDS-related or non-AIDS-related Kaposi's sarcoma (KS) will be treated with varying doses of the drug sorafenib (Nexavar®) for up to 54 weeks to examine the safety of the drug and determine how it is processed in patients with KS who are receiving antiretroviral therapy.
- Treatment for Castleman Disease
(Posted: 12/13/2005) - In this clinical trial, symptomatic patients with multicentric Castleman disease (MCD) will be treated with the antiviral drugs high-dose zidovudine (HDAZT) and valganciclovir. These drugs are converted into toxic compounds by KSHV-encoded proteins. Patients who do not respond to this treatment will also receive the drug bortezomib to see if it can increase the ability of KSHV to activate HDAZT and valganciclovir and increase tumor cell death.